Linde Healthcare Continues to Support Innovation in Advanced Respiratory Care

Linde Healthcare, a global business of The Linde Group, has announced the new beneficiaries of its REALfund initiative, a programme supporting ideas and projects with the potential to improve patient outcomes and health economics across the wide field of respiratory medicine.

Selected from many high quality applications from leading clinics and research organisations around the world, three grantees of the REALfund will receive funds to support their innovative research:

  • PD Johannes Bickenbach MD and Professor Michael Dreher MD, University Hospital Aachen, Germany, will investigate if exacerbations of invasively mechanically ventilated COPD patients can be predicted by an algorithm based on software analysis of data which will be read out from the ventilator.
  • Thomas Bitter MD, Heart and Diabetes Centre Bad Oeynhausen, Germany, will study if high flow oxygen therapy could serve as a new therapeutic approach to treat patients suffering from Cheyne-Stokes respiration associated with Chronic Heart Failure.
  • Professor Christopher H. Fanta MD, Brigham and Women’s hospital, Harvard Medical School, Boston, USA, plans to develop a smartphone app which is able to alert COPD patients about deterioration in their breathing and to provide recommendations for patient-initiated first actions to prevent serious exacerbations of their conditions.

Dr Christian Wojczewski, Head of Linde Healthcare states: "Linde Healthcare continues to be committed to co-operating with researchers from around the world to support research and innovative developments in the area of respiratory medicine. The newly awarded REALfund grants fit very well into Linde Healthcare's footprint as global healthcare organisation specialising along an integrated respiratory care path. The work of these researchers, when realised, will help healthcare professionals, support healthcare systems and further improve the quality of care and life for patients."

Grantees of the REALfund are selected with the help of medical and scientific experts and will be supported in their continued research. Dr Konstantin Fiedler, Head of Innovation at Linde Healthcare states: "The aim of Linde Healthcare’s REALfund initiative is to seek and reward ideas that have real potential to be developed into better respiratory care solutions for patients. We are proud of having received many high-quality applications from different regions around the world. We commend all applicants to the fund for their commitment to innovation and idea development in this area of healthcare. The grantees saw the potential in their projects and we at Linde Healthcare are delighted to recognise and reward the ideas that will truly benefit patients."

For further information about the REALfund, please visit:
http://www.linde-realfund.com

About Linde Healthcare
Linde Healthcare is a global leader specialising along an integrated respiratory care path. It combines pharmaceutical gases, medical devices, services and clinical care into solutions with the patient in mind. Its products and services make a difference in the lives of its patients and to its healthcare partners in the care continuum from hospital to home. A global business unit of The Linde Group, it is present in over 60 countries and generated revenues of EUR 3.059 bn in 2014 and employs 16,643 employees.

About The Linde Group
In the 2014 financial year, The Linde Group generated revenue of EUR 17.047 bn, making it the largest gases and engineering company in the world with approximately 65,500 employees working in more than 100 countries worldwide. The strategy of The Linde Group is geared towards long-term, profitable growth and focuses on the expansion of its international business with forward-looking products and services. Linde acts responsibly towards its shareholders, business partners, employees, society and the environment - in every one of its business areas, regions and locations across the globe. The company is committed to technologies and products that unite the goals of customer value and sustainable development.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...